In this study, we compared the clinicopathological characteristics of patients of Group 2 and Group 5 (i.e. classic HER2-nonamplified cancer with HER2/CEP17 ratio less than 2.0) to determine whether there is a significant difference between these two groups. The gene discussed is ERBB2; the disease is cancer.